Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma

pharmanewsdaily- April 28, 2020

Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More

Innovent Biologics and Incyte announce $391.5m partnership for cancer drugs in China

pharmanewsdaily- December 17, 2018

Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational ... Read More